Posts Tagged ‘Diabetic Macular Edema’
Eleven Biotherapeutics
Eleven Biotherapeutics is using its proprietary AMP-Rx protein-engineering platform to develop agents for more effective treatment of allergic conjunctivitis as well as to investigate new treatments for patients with diabetic macular edema (DME) who do not respond to anti-VEGF therapy. In October, the company had completed enrollment in its double-masked, randomized, vehicle-controlled Phase III pivotal…
Read MoreAlimera
Alimera Sciences is “dedicated to change the paradigm of how we think about and subsequently treat diabetic macular edema (DME),” Mr. Myers said. Iluvien is a fluocinolone (corticosteroid) implant for the treatment of DME. One implant releases 0.2 mcg per day, giving patients up to 3 years’ worth of therapy. Iluvien is “a real advancement…
Read MoreEnvisia Therapeutics
This company, founded as a spin-out of Liquidia Technologies in 2013, began with a $25 million Series A, with the goal of developing the PRINT particle platform for ophthalmic indications. The PRINT platform can be applied to make “very precise drug delivery systems for the eye,” Dr. Yerxa said, as anything that can be manufactured…
Read MoreEleven Biotherapeutics
Presenter: Abbie C. Celniker, PhD Dr. Celniker brings more than 20 years of proven protein therapeutic expertise to Eleven Biotherapeutics. Prior to joining Eleven, Abbie was CEO of Taligen Therapeutics, which was acquired by Alexion Pharmaceuticals. View Full Profile
Read MoreAlimera CEO Myers Shares Lessons From Iluvien FDA Approval
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 018″] The FDA turned away Alimera Sciences’ bid to market Iluvien as a treatment for diabetic macular edema three times before finally giving the green light. President & CEO Dan Myers shares what kept his confidence up during this lengthy review and how Alimera Sciences is positioning Iluvien in the DME…
Read MoreNeurotech
Quinton Oswold, President and CEO of Neurotech Pharmaceuticals Inc., sees huge opportunity both in wet AMD and diabetic macular edema patients who need more extensive and longer lasting therapies. Neurotech’s Encapsulated Cell Technology (ECT) platform provides long-term continuous delivery (2+years) of protein drugs directly into the vitreous of the eye. The company is developing multiple…
Read MoreAlimera Sciences
Alimera Sciences Inc. is ready to launch in the US its recently approved intravitreal implant, Iluvien, for treating diabetic macular edema. President and CEO Dan Myers reported the company has a direct sales force of 32 reps ready for the product’s commercial debut in Q1 2015. Iluvien delivers a corticosteroid, providing sustained therapeutic effect for…
Read MoreAvalanche Biotechnologies Gives Ocular BioFactory Tour
Thomas W. Chalberg, PhD presented an update on Avalanche Biotechnologies Inc.’s pipeline of products emerging from its integrated gene therapy discovery, development, and manufacturing platform, Ocular BioFactory. Avalanche’s lead product, AVA-101, is undergoing Phase IIa clinical trials for wet AMD; the company could submit an investigational new drug applications in the second half of 2015.…
Read MoreAllegro Gives Phase II News on Luminate
[creativ_media type=”vimeo” url=”https://vimeo.com/110730931″] Vicken Karageozian, MD, Co-Founder and CTO of Allegro Opthalmics LLC, updated the OIS audience on the clinical trial progress of Luminate, a first-in-class integrin peptide therapy that treats vitreo-retinal diseases by utilizing two mechanisms of action, anti-angiogenesis and vitreolysis. The company just initiated a Phase II study of the drug as a…
Read MoreEleven Biotherapeutics
Presenter: Abbie C. Celniker, PhD Dr. Celniker brings more than 20 years of proven protein therapeutic expertise to Eleven Biotherapeutics. Prior to joining Eleven, Abbie was CEO of Taligen Therapeutics, which was acquired by Alexion Pharmaceuticals. View Full Profile
Read MoreiCo Therapeutics Sidesteps VEGF in Diabetic Macular Edema
iCo Therapeutics – Andrew Rae, President & CEO for iCo Therapeutics, shares the company’s focus on diabetic macular edema and their 187 patient study, which is fully enrolled in the U.S. Viewing an opportunity to better serve this population, ICO Therapeutics talks about their products that provide improved outcomes for patients not responding or only…
Read MoreEleven Biotherapeutics Gets to the Root of Ophthalmic Diseases
Eleven Biotherapeutics – Abbie Celniker, CEO for Eleven Biotherapeutics, provides the audience at the 5th Annual Ophthalmology Innovation Summit with an update on her company’s progress over the past year. Highlighting their company’s focus on understanding the biology of key targets in ophthalmic diseases and creating protein therapeutics to treat them, Abbie details the current…
Read More